These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Decreased immunoexpression of prostate inhibin peptide in prostatic carcinoma: a study with monoclonal antibody. Zhang PJ; Driscoll DL; Lee HK; Nolan C; Velagapudi SR Hum Pathol; 1999 Feb; 30(2):168-72. PubMed ID: 10029444 [TBL] [Abstract][Full Text] [Related]
23. Expression of estrogen receptor-B ( ER-B ) in bengin and malignant prostatic epithelial cells and its correlation with the clinico-pathological features. Gabal SM; Habib FM; Helmy DO; Ibrahim MF J Egypt Natl Canc Inst; 2007 Dec; 19(4):239-48. PubMed ID: 19672287 [TBL] [Abstract][Full Text] [Related]
24. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer. Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494 [TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis of intraductal proliferative lesions of prostate: intraductal carcinoma of prostate, high-grade prostatic intraepithelial neoplasia, and atypical cribriform lesion. Miyai K; Divatia MK; Shen SS; Miles BJ; Ayala AG; Ro JY Hum Pathol; 2014 Aug; 45(8):1572-81. PubMed ID: 24842280 [TBL] [Abstract][Full Text] [Related]
26. Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression. Sroka IC; McDaniel K; Nagle RB; Bowden GT Prostate; 2008 Apr; 68(5):463-76. PubMed ID: 18196535 [TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia. Hasby EA; Saied EM J Egypt Natl Canc Inst; 2008 Jun; 20(2):158-67. PubMed ID: 20029472 [TBL] [Abstract][Full Text] [Related]
28. MAGI-2 in prostate cancer: an immunohistochemical study. Goldstein J; Borowsky AD; Goyal R; Roland JT; Arnold SA; Gellert LL; Clark PE; Hameed O; Giannico GA Hum Pathol; 2016 Jun; 52():83-91. PubMed ID: 26980016 [TBL] [Abstract][Full Text] [Related]
29. Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland. Lazari P; Poulias H; Gakiopoulou H; Thomopoulou GH; Barbatis C; Lazaris AC Urol Int; 2013; 90(1):109-16. PubMed ID: 23220849 [TBL] [Abstract][Full Text] [Related]
30. Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate. Rodríguez-Berriguete G; Fraile B; de Bethencourt FR; Prieto-Folgado A; Bartolome N; Nuñez C; Prati B; Martínez-Onsurbe P; Olmedilla G; Paniagua R; Royuela M BMC Cancer; 2010 Jan; 10():18. PubMed ID: 20078866 [TBL] [Abstract][Full Text] [Related]
31. [The morphogenesis of cancer of the prostate (immunohistochemical research)]. Vorobĭova LR Lik Sprava; 1998 May; (3):87-90. PubMed ID: 9695575 [TBL] [Abstract][Full Text] [Related]
32. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens. Helpap B Virchows Arch; 2006 Apr; 448(4):480-4. PubMed ID: 16506014 [TBL] [Abstract][Full Text] [Related]
33. Expression patterns of potential therapeutic targets in prostate cancer. Zellweger T; Ninck C; Bloch M; Mirlacher M; Koivisto PA; Helin HJ; Mihatsch MJ; Gasser TC; Bubendorf L Int J Cancer; 2005 Feb; 113(4):619-28. PubMed ID: 15472903 [TBL] [Abstract][Full Text] [Related]
34. p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. Ferronika P; Triningsih FX; Ghozali A; Moeljono A; Rahmayanti S; Shadrina AN; Naim AE; Wudexi I; Arnurisa AM; Nanwani ST; Harijadi A Asian Pac J Cancer Prev; 2012; 13(5):1943-8. PubMed ID: 22901151 [TBL] [Abstract][Full Text] [Related]
35. PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Pan CX; Kinch MS; Kiener PA; Langermann S; Serrero G; Sun L; Corvera J; Sweeney CJ; Li L; Zhang S; Baldridge LA; Jones TD; Koch MO; Ulbright TM; Eble JN; Cheng L Clin Cancer Res; 2004 Feb; 10(4):1333-7. PubMed ID: 14977833 [TBL] [Abstract][Full Text] [Related]
36. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score. Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460 [TBL] [Abstract][Full Text] [Related]
37. Differential up-regulation of erythropoietin and its receptor in benign and malignant prostatic tissue. Xu C; Zhou T; He M; Sun Y Urol Oncol; 2010; 28(3):314-9. PubMed ID: 19070519 [TBL] [Abstract][Full Text] [Related]
38. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma. Jia X; Sun Y; Wang B IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296 [TBL] [Abstract][Full Text] [Related]
39. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis. Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353 [TBL] [Abstract][Full Text] [Related]
40. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions. Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]